Vaccibody Financial Statements From 2010 to 2024
| VACCDelisted Stock | USD 2.23 0.04 1.83% |
Check Vaccibody financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vaccibody's main balance sheet or income statement drivers, such as , as well as many indicators such as . Vaccibody financial statements analysis is a perfect complement when working with Vaccibody Valuation or Volatility modules.
Vaccibody |
Vaccibody As Company Return On Equity Analysis
Vaccibody's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Vaccibody Return On Equity | -0.23 |
Most of Vaccibody's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Vaccibody As is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, Vaccibody As has a Return On Equity of -0.2329. This is 99.03% lower than that of the Biotechnology sector and 99.36% lower than that of the Health Care industry. The return on equity for all Norway stocks is 24.87% lower than that of the firm.
Vaccibody As Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Vaccibody's current stock value. Our valuation model uses many indicators to compare Vaccibody value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Vaccibody competition to find correlations between indicators driving Vaccibody's intrinsic value. More Info.Vaccibody As is rated fifth in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Vaccibody by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Vaccibody's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Vaccibody Financial Statements
Vaccibody stakeholders use historical fundamental indicators, such as Vaccibody's revenue or net income, to determine how well the company is positioned to perform in the future. Although Vaccibody investors may analyze each financial statement separately, they are all interrelated. For example, changes in Vaccibody's assets and liabilities are reflected in the revenues and expenses on Vaccibody's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Vaccibody As. Please read more on our technical analysis and fundamental analysis pages.
Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom. Vaccitech Plc operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 72 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Other Consideration for investing in Vaccibody Stock
If you are still planning to invest in Vaccibody As check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Vaccibody's history and understand the potential risks before investing.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |